| Literature DB >> 24366606 |
Angelantonio Notarangelo1, Domenico Trombetta2, Vincenzo D'Angelo3, Paola Parrella2, Orazio Palumbo1, Clelia Tiziana Storlazzi4, Luciana Impera4, Lucia Anna Muscarella2, Antonella La Torre2, Andrea Affuso5, Vito Michele Fazio2, Massimo Carella1, Leopoldo Zelante1.
Abstract
Glioblastoma multiforme (World Health Organization, grade IV astrocytoma) is the most common and most aggressive malignant primary brain tumor. We report a novel cell line, designated as ANGM-CSS, which was established from a 56-year-old male patient with a surgically removed glioblastoma multiforme. The ANGM-CSS cell line was established in vitro and characterized using histological and immunohistochemical staining, classical and molecular cytogenetic analyses, molecular studies and functional assays using a xenograft model in immunodeficient animals. ANGM-CSS was positive for CD133, nestin and vimentin proteins, whereas GFAP showed staining only in a fraction of the cells. Cytogenetic and molecular cytogenetic analysis revealed a near-tetraploid karyotype, with a modal chromosome number from 88 to 91, and additional cytogenetic abnormalities, such as the t(6;14)(p12;q11.2), t(8;10)(q24.2;q21.1) and t(5;9)(q34;p21) unbalanced translocations. Moreover, ANGM-CSS showed amplification of the MET and EGFR genes whose overexpression was observed at the mRNA level. Interestingly, ANGM-CSS is tumorigenic when implanted in immunodeficient mice, and the cells obtained from the xenografts showed the same morphology and karyotype in vitro as the original cell line. ANGM-CSS represents a biologically relevant cell line to be used to investigate the molecular pathology of glioblastoma multiforme, also to evaluate the efficacy of novel therapeutic drugs in vitro.Entities:
Mesh:
Year: 2013 PMID: 24366606 DOI: 10.3892/ijo.2013.2224
Source DB: PubMed Journal: Int J Oncol ISSN: 1019-6439 Impact factor: 5.650